Valuation: PFIZER

Market Cap 164B 164B 144B 137B 124B 232B 15,708B 235B 1,640B 632B 8,021B 615B 601B 25,812B P/E 2026 *
18.1x
P/E 2027 * 14x
Enterprise Value 211B 211B 186B 176B 160B 300B 20,264B 303B 2,115B 815B 10,348B 793B 776B 33,299B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 3.42x
Free-Float
59.05%
Yield 2026 *
5.99%
Yield 2027 * 6.04%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 55 16/08/2026
Compliance Officer 65 01/12/2013
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%+0.84%+62.42%+119.69% 1,056B
-1.94%-0.98%+46.77%+71.15% 655B
-1.10%-0.71%+18.00%+76.66% 471B
-1.72%-4.06%+36.39%+39.47% 342B
-0.40%+3.83%+22.08%+28.82% 277B
-0.51%-1.93%+12.09%+11.94% 257B
+0.45%+2.26%+53.12%+56.09% 226B
-1.06%-1.44%+33.61%+100.79% 189B
-0.24%-2.76%-28.41%-60.92% 170B
Average -0.77%+0.97%+28.45%+49.30% 404.77B
Weighted average by Cap. -0.86%+1.04%+38.50%+70.01%

Financials

2026 *2027 *
Net sales 62.24B 62.24B 54.92B 51.97B 47.13B 88.35B 5,972B 89.23B 623B 240B 3,050B 234B 229B 9,813B 59.77B 59.77B 52.74B 49.9B 45.26B 84.85B 5,735B 85.69B 599B 231B 2,929B 224B 220B 9,424B
Net income 8.9B 8.9B 7.85B 7.43B 6.74B 12.64B 854B 12.76B 89.15B 34.36B 436B 33.42B 32.69B 1,403B 11.08B 11.08B 9.78B 9.25B 8.39B 15.73B 1,063B 15.89B 111B 42.78B 543B 41.61B 40.7B 1,747B
Net Debt 47.48B 47.48B 41.9B 39.65B 35.96B 67.41B 4,556B 68.08B 476B 183B 2,327B 178B 174B 7,487B 40.98B 40.98B 36.17B 34.22B 31.03B 58.18B 3,932B 58.75B 410B 158B 2,008B 154B 151B 6,462B
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A